Blood loss is the primary cause of death in both battlefield and civilian trauma. We address internal bleeding with nanoparticles designed to augment hemostasis after intravenous delivery.Nanoparticles are synthesized from block copolymer consisting of poly(lactic-co-glycolic acid), poly(L-lysine), and poly(ethylene glycol).  The platelet-targeting peptide RGD is conjugated to PEG to functionalize the particles.  Mice are subjected to a 20psi blast injury followed by treatment to test effectiveness of these particles in blast trauma.One-hour lethality data indicates survival for mice treated with active particles is 22 times that of the untreated control group and 9 times that of mice treated with non-targeted particles with a 95% confidence interval.  Biodistribution shows the majority of particles go to the lungs, spleen, and liver following injury.  Preliminary histology demonstrates reduced lung injury in treated mice.Synthetic platelets significantly improve survival following blast injury and have the potential to fundamentally change blast treatment.

Intravenously administered nanoparticles increase survival in blast trauma

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.